title: Assessment of OPG, RANKL, bone turnover markers serum levels and BMD after treatment with strontium ranelate and ibandronate in patients with postmenopausal osteoporosis.
abstract: BACKGROUND
  The aim of this study was to evaluate quantitative changes in OPG and RANKL proteins after treatment with strontium ranelate (SR) and ibandronate in patients with postmenopausal osteoporosis.
  
  
  METHODS
  A total of 89 women with postmenopausal osteoporosis (PO), aged 51-85 years, patients of the Outpatient Clinic of Osteoporosis of the Military Teaching Hospital in Lodz, were enrolled in the study. The patients were randomly assigned to different therapies: ibandronate and (SR). Patients of the control group received only calcium and vitamin D3 supplements. The patients' visits were repeated after three and six months. Measurements of beta-CTX (C-terminal Telopeptide of type 1 collagen), osteocalcin, RANKL, osteoprotegerin (OPG), alkaline phosphatase concentrations in serum, as well as of total 24-hour calcium and phosphate levels in serum and urine, were carried out in material collected at baseline and after three and six months of therapy. Left hip and lumbar spine densitometry was done twice (at baseline visit and after six months).
  
  
  RESULTS
  In all three groups there were no significant differences noted in the concentrations of OPG and RANKL serum protein levels during the study period. Both negative and positive correlations or tendencies of correlations were found between OPG serum concentrations and BMD changes in the SR group.
  
  
  CONCLUSIONS
  Both ibandronate and SR do not seem to cause any significant changes in OPG and RANKL protein serum levels during the first six months of treatment. OPG may play a role in osteoclast activity suppression in the course of treatment with ibandronate in patients with PO. OPG may play an important role in the mechanism of SR therapy and may be viewed as a potentially valuable parameter for monitoring and predicting the course of treatment with SR in PO.
authors.affiliation: Department of Endocrine Disorders and Bone Metabolism, Medical University of Lodz, Lodz, Poland; Outpatient Clinic of Osteoporosis, of Military Teaching Hospital in Lodz, Poland. mstuss@wp.pl.
authors.forename: Michał
authors.initials: M
authors.lastname: Stuss
authors.forename: Ewa
authors.initials: E
authors.lastname: Sewerynek
authors.forename: Iwona
authors.initials: I
authors.lastname: Król
authors.forename: Wioletta
authors.initials: W
authors.lastname: Stępień-Kłos
authors.forename: Sławomir
authors.initials: S
authors.lastname: Jędrzejczyk
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood / Q000187:drug effects; D016723:Bone Remodeling / Q000187:drug effects; D004164:Diphosphonates / Q000494:pharmacology* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D000077557:Ibandronic Acid; D008875:Middle Aged; D015675:Osteocalcin / Q000097:blood / Q000187:drug effects; D015663:Osteoporosis, Postmenopausal / Q000097:blood* / Q000188:drug therapy; D053244:Osteoprotegerin / Q000097:blood* / Q000187:drug effects; D053245:RANK Ligand / Q000097:blood* / Q000187:drug effects; D013876:Thiophenes / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D004164:Diphosphonates; D053244:Osteoprotegerin; D053245:RANK Ligand; C506030:TNFRSF11B protein, human; C505688:TNFSF11 protein, human; D013876:Thiophenes; C081587:strontium ranelate; D015675:Osteocalcin; D000469:Alkaline Phosphatase; D000077557:Ibandronic Acid
keywords: RANKL; ibandronate; osteoporosis; osteoprotegerin; strontium ranelate